Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 7/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5332947 | 0.98 | SLC9A1 (0.53) | SLC9A1P2RX7ADRA1DHTR2AADRA1B | |
| SCHEMBL5335562 | 0.93 | SLC9A1 (0.51) | SLC9A1P2RX7MEN1LMNAKMT2A | |
| SCHEMBL5334211 | 0.91 | SLC9A1 (0.56) | SLC9A1P2RX7ADRA1DHTR2AADRA1B | |
| SCHEMBL5331703 | 0.89 | SLC9A1 (0.54) | SLC9A1P2RX7ADRA1DHTR2AADRA1B | |
| SCHEMBL5337528 | 0.88 | P2RX7 (0.55) | SLC9A1P2RX7ADRA1DHTR2AADRA1B | |
| SCHEMBL5334033 | 0.87 | SLC9A1 (0.62) | SLC9A1P2RX7ADRA1DHTR2AADRA1B | |
| SCHEMBL5332540 | 0.86 | SLC9A1 (0.52) | SLC9A1P2RX7ADRA1DHTR2AADRA1B | |
| SCHEMBL5333085 | 0.85 | SLC9A1 (0.63) | SLC9A1P2RX7ADRA1DHTR2AADRA1B | |
| SCHEMBL5345970 | 0.84 | SLC9A1 (0.59) | SLC9A1P2RX7ADRA1DHTR2AADRA1B | |
| SCHEMBL5345185 | 0.84 | SLC9A1 (0.52) | SLC9A1P2RX7MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155795-A1 | MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-7238713-B2 | Muscarinic agonists | ACADIA PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1535912-A1 | Muscarinic agonists | Arcadia Pharmaceuticals Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050113357-A1 | Muscarinic agonists | ANDERSON CARL-MAGNUS A (DK) | 2005-05-26 | — | — | US | disclosed |
| US-6627645-B2 | Cholinergic agents | ACADIA PHARMACEUTICALS, INC. | 2003-09-30 | — | — | US | disclosed |
| US-20020037886-A1 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037886-A1 | Muscarinic agonists | CHRM2, CHRM1, CHRM4 | SLC9A1 3562/4885P2RX7 731/4885ADRA1D 28/4885 |
| US-20070155795-A1 | MUSCARINIC AGONISTS | CHRM2, CHRM1, CHRM4 | SLC9A1 3562/4885P2RX7 731/4885ADRA1D 28/4885 |
| US-20050113357-A1 | Muscarinic agonists | CHRM2, CHRM1, CHRM4 | SLC9A1 3562/4885P2RX7 731/4885ADRA1D 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.